Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Global Blood Therapeutics Inc.

www.gbt.com

Latest From Global Blood Therapeutics Inc.

Pfizer Ends Pact With GlycoMimetics After SCD Failure

GlycoMimetics’ commercial and pipeline prospects are in doubt after Pfizer terminated their 2011 sickle cell drug development deal, following a failed late-stage study.

Companies Deals

ICER Will Assess Real World Evidence On Accelerated Approvals After Two Years

Process will incorporate real world evidence into future cost effectiveness updates of already reviewed drugs to supplement the information available prior to launch.

Health Technology Assessment Pharmacy Benefit Management

US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected

Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).

Drug Review Drug Approval Standards

Neuroscience Challenges Oncology For Top Spot In CDER’s 2019 Novel Approvals

Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.

Review Pathway Pink Sheet Perspectives
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Global Blood Therapeutics Inc.
  • Senior Management
  • Ted W Love, MD, Pres. & CEO
    Jeffrey Farrow, CFO
    Jung E Choi, Chief Bus. & Strategy Officer
    David L Johnson, Chief Commercial Officer
    Brian Cathers, PhD, CSO
  • Contact Info
  • Global Blood Therapeutics Inc.
    Phone: (650) 741-7700
    171 Oyster Point Blvd.
    Ste. 300
    South San Francisco, CA 94080
    USA
UsernamePublicRestriction

Register